CEPHALOTAXINE 4-METHYL (2R)-2-HYDROXY-2-(4-HYDROXY-4-METHYLPENTYL)BUTANEDIOATE (ESTER)
Acute Myeloid Leukemia, FLT3 Internal Tandem Duplication
The University of Hong KongSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
10 Active assets in the Acute Myeloid Leukemia, FLT3 Internal Tandem Duplication cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Gilteritinib The First Affiliated Hospital of Soochow University | Phase 3 | BB |
Azacitidine French Innovative Leukemia Organisation | Phase 2 | BB |
CYTARABINE First Affiliated Hospital of Zhejiang University | Phase 3 | BB |
Sorafenib The First Affiliated Hospital of Soochow University | Phase 3 | BB |
Quizartinib M.D. Anderson Cancer Center | Phase 2 | BB |
View all 21 →
Same molecule, other indications
CEPHALOTAXINE 4-METHYL (2R)-2-HYDROXY-2-(4-HYDROXY-4-METHYLPENTYL)BUTANEDIOATE (ESTER) is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →